Prognostic Factors for Survival in Transverse Colon Cancers

Basit Öğe Kaydı
dc.authoridHacioglu, Bekir/0000-0001-8490-3239
dc.authoridKucukarda, Ahmet/0000-0001-7399-2360
dc.authoridSayin, Sezin/0000-0001-7892-5992
dc.authorwosidErdogan, Bulent/AAA-9781-2021
dc.authorwosidHacioglu, Bekir/GZH-1824-2022
dc.authorwosidKüçükarda, Ahmet/AGF-2120-2022
dc.contributor.authorKucukarda, Ahmet
dc.contributor.authorGokyer, Ali
dc.contributor.authorSayin, Sezin
dc.contributor.authorGokmen, Ivo
dc.contributor.authorOzcan, Erkan
dc.contributor.authorKostek, Osman
dc.contributor.authorHacioglu, Muhammet Bekir
dc.date.accessioned2024-06-12T11:16:37Z
dc.date.available2024-06-12T11:16:37Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground Transverse colon cancer (TCC) is a rare condition that accounts for 10% of all colon cancers. TCC was accepted more likely right-sided colon cancers. We aimed to investigate whether TCC differs from other colon tumors by using clinical, pathological, and molecular prognostic factors known to be important in colon cancer and if it differs in its own anatomical structure. Patients and Methods We evaluated local and locally advanced TCC patients between 2007 and 2020 years for demographics data, symptoms, treatment status, and histopathological and molecular features. Results Overall, 107 TCC patients were included in this study. According to the molecular data analysis of 44, 35, and 23 patients for MSI, RAS, and BRAF status, respectively, 7 (15.9%) were MSI-H, 13 (37.1%) were RAS mutant, and 11 (47.8%) had BRAF V600E mutation. The median follow-up time was 31.5 months. Median disease-free survival (DFS) was 5.19 months, and median OS was 88.3 months for the whole study population. The tumor stage was the most significant prognostic factor for DFS and OS. Although BRAF mutation was not a significant marker for DFS, it was an independent prognostic marker for OS (HR 3.90 95% CI 1.42-10.7). There were no statistically significant differences between proximal two-thirds and distal one-third tumor location. Conclusion TCC has molecular features and prognostic factors more likely RCC and no differences between proximal and distal sub-parts. BRAF V600E mutation status is an independent predictor of survival even in the early stages of TCC.en_US
dc.identifier.doi10.1007/s12029-021-00675-1
dc.identifier.endpage40en_US
dc.identifier.issn1941-6628
dc.identifier.issn1941-6636
dc.identifier.issue1en_US
dc.identifier.pmid34302255en_US
dc.identifier.scopus2-s2.0-85111108731en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage31en_US
dc.identifier.urihttps://doi.org/10.1007/s12029-021-00675-1
dc.identifier.urihttps://hdl.handle.net/20.500.14551/24388
dc.identifier.volume53en_US
dc.identifier.wosWOS:000676083800001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal Of Gastrointestinal Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectTransverse Colon Canceren_US
dc.subjectPrognosisen_US
dc.subjectSurvivalen_US
dc.subjectBRAF V600Een_US
dc.subjectPathological Stageen_US
dc.subjectColorectal-Canceren_US
dc.subjectMicrosatellite-Instabilityen_US
dc.subjectAdjuvant Chemotherapyen_US
dc.subjectProximal Colonen_US
dc.subjectStage-Iien_US
dc.subjectFluorouracilen_US
dc.subjectMutationen_US
dc.titlePrognostic Factors for Survival in Transverse Colon Cancersen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu